Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Lung Neoplasms 1Endometrial Neoplasms 1

Interventions

Carboplatin 14pembrolizumab 13Specimen Handling 9Paclitaxel 6Magnetic Resonance Spectroscopy 5Capecitabine 5Biopsy 5Nivolumab 4Cyclophosphamide 4sacituzumab govitecan 3Gemcitabine 3Fulvestrant 3olaparib 2fludarabine 2atezolizumab 2aldesleukin 2Taxes 2Letrozole 2Epirubicin 2Docetaxel 2Cisplatin 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2zimberelimab 1veliparib 1trastuzumab deruxtecan 1toripalimab 1sintilimab 1pyrotinib 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × CP protocol × 30 days × Clear all
NCT07610525 2026-05-28

Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial

M.D. Anderson Cancer Center

Phase 2 Not yet recruiting
200 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡